Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed FCF Margin for 5 consecutive years, with 44.35% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 71.0% to 44.35% in Q4 2025 year-over-year; TTM through Dec 2025 was 60.96%, a 2655.0% increase, with the full-year FY2025 number at 61.46%, up 2605.0% from a year prior.
  • FCF Margin was 44.35% for Q4 2025 at Rhythm Pharmaceuticals, up from 51.9% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 422.45% in Q4 2022 to a low of 95837.14% in Q1 2021.
  • A 5-year average of 6053.56% and a median of 143.44% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 9224842bps in 2022, then crashed -54370bps in 2023.
  • Rhythm Pharmaceuticals' FCF Margin stood at 2231.15% in 2021, then skyrocketed by 119bps to 422.45% in 2022, then plummeted by -129bps to 121.24% in 2023, then surged by 63bps to 45.05% in 2024, then rose by 2bps to 44.35% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's FCF Margin are 44.35% (Q4 2025), 51.9% (Q3 2025), and 48.07% (Q2 2025).